Infanrix-Ipv (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A)

Infanrix-Ipv is a combination vaccine that targets viral and bacterial pathogens responsible for poliomyelitis type 3 and pertussis.

• Poliomyelitis type 3: Provides active immunity to prevent infection with poliovirus type 3 in infants and young children.
• Pertussis (whooping cough): Induces protective antibodies against pertussis filamentous haemagglutinin to reduce incidence of whooping cough.
• Combined immunisation schedule: Facilitates inclusion in routine childhood vaccination programs, simplifying protection against both diseases.

• Infanrix-Ipv contains inactivated poliovirus type 3 particles and purified pertussis filamentous haemagglutinin adsorbed onto an adjuvant. After intramuscular injection, antigen‑presenting cells process the viral capsid proteins and bacterial haemagglutinin, presenting them to T‑cells. This stimulates B‑cell activation and production of neutralising antibodies against poliovirus and pertussis antigens, establishing active humoral immunity. The generated memory B‑cells enable rapid response upon future exposure, while helper T‑cells support the antibody response.

Infanrix-Ipv, like other injectable vaccines, may be associated with local and systemic reactions.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema or edema that resolves within a few days.
• Low‑grade fever: temperature rise up to 38 °C occurring within 24‑48 hours.
• Irritability or fussiness: especially in infants after vaccination.
• Headache: transient mild headache reported by some recipients.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Seizures: febrile seizures associated with high fever post‑vaccination.
• Persistent high fever: temperature above 39 °C lasting more than 48 hours.
• Apnea in young infants: brief pauses in breathing observed rarely.
• Guillain‑Barré syndrome: extremely rare demyelinating neuropathy reported post‑immunisation.

Before administering Infanrix-Ipv, healthcare professionals should observe several precautionary measures.

• Contraindication: Do not vaccinate individuals with a documented severe allergic reaction to any vaccine component.
• Acute illness: Postpone vaccination if the patient has a moderate or severe febrile illness.
• Immunocompromised status: Evaluate risks in severely immunocompromised patients, although the vaccine is inactivated.
• Pregnancy: Use only if the benefit outweighs potential risk, following professional guidance.
• Monitoring: Observe the patient for at least 15 minutes after injection for signs of anaphylaxis.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Infanrix-Ipv may interact with other medical products; awareness of potential interactions is important.

Major Interactions (Avoid)

• Live viral vaccines: Avoid simultaneous administration with live attenuated vaccines such as measles‑mumps‑rubella, as it may reduce immune response.
• Immunoglobulin therapy: Do not give within 2 weeks of immune globulin, which can interfere with antibody development.

Moderate Interactions (Monitor Closely)

• Other inactivated vaccines: Co‑administration is generally acceptable but monitor for increased reactogenicity.
• Antipyretics: Use of prophylactic acetaminophen may blunt antibody response; consider timing.
• Corticosteroids: High‑dose steroids may diminish vaccine efficacy; assess patient’s steroid regimen.